drugset / Trial / NCT00955318

Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease

NCT00955318

Phase 3 Completed 58 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of KW-6500 when administered as long-term subcutaneous self-injections in Parkinson's disease patients with motor response complications on levodopa therapy.

Timeline

Start
2009-07
Primary completion
2010-12
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Apomorphine Unknown 1 mg Subcutaneous
Subject Apomorphine Unknown 6 mg Subcutaneous

Indications